The current financial score of Beta Bionics Inc is 7.26. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 32.01M, representing a year-over-year increase of 37.76%, while its net profit experienced a year-over-year increase of 38.73%.
The current valuation score of Beta Bionics Inc is 8.55. Its current P/E ratio is -16.25, which is -69.80% below the recent high of -4.91 and -14.72% above the recent low of -18.64.
The current earnings forecast score of Beta Bionics Inc is 8.18. The average price target is 22.87, with a high of 30.40 and a low of 16.00.
The current price momentum score of Beta Bionics Inc is 5.77. Currently, the stock price is trading between the resistance level at 25.33 and the support level at 17.28, making it suitable for range-bound swing trading.
The current institutional shareholding score of Beta Bionics Inc is 10.00. The latest institutional shareholding proportion is 110.51%, representing a quarter-over-quarter increase of 4.12%.
The current risk assessment score of Beta Bionics Inc is 4.45. The company's beta value is 0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.